CAS 354813-19-7
:Balicatib
Description:
Balicatib, with the CAS number 354813-19-7, is a chemical compound that functions primarily as a selective inhibitor of cathepsin K, an enzyme involved in bone resorption. This characteristic makes Balicatib of particular interest in the treatment of osteoporosis and other bone-related disorders, as it helps to reduce bone loss by inhibiting the activity of osteoclasts, the cells responsible for bone degradation. The compound is typically characterized by its specific molecular structure, which allows it to bind effectively to the active site of cathepsin K. Balicatib has been studied for its pharmacokinetic properties, including absorption, distribution, metabolism, and excretion, which are crucial for determining its efficacy and safety profile in clinical settings. Additionally, its potential side effects and interactions with other medications are important considerations in its therapeutic use. Overall, Balicatib represents a targeted approach in the management of conditions associated with excessive bone resorption.
Formula:C23H33N5O2
InChI:InChI=1S/C23H33N5O2/c1-2-14-27-15-17-28(18-16-27)20-8-6-19(7-9-20)21(29)26-23(10-4-3-5-11-23)22(30)25-13-12-24/h6-9H,2-5,10-11,13-18H2,1H3,(H,25,30)(H,26,29)
InChI key:LLCRBOWRJOUJAE-UHFFFAOYSA-N
SMILES:CCCN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3(CCCCC3)C(=O)NCC#N
Synonyms:- Aae-581
Filter by
Purity percentage
0
100
|
0
|
50
|
90
|
95
|
100
Found 6 products.
- Lower prices
- Higher prices
- Lower purities
- Higher purities
- Faster estimated delivery
N-(1-((Cyanomethyl)Carbamoyl)Cyclohexyl)-4-(4-Propylpiperazin-1-Yl)Benzamide
CAS:N-(1-((Cyanomethyl)Carbamoyl)Cyclohexyl)-4-(4-Propylpiperazin-1-Yl)BenzamideFormula:C23H33N5O2Purity:98+%Molecular weight:411.54Balicatib
CAS:Balicatib (AAE581) is a potent and selective inhibitor of cathepsin K, used in trials studying the treatment of osteoporosis.Formula:C23H33N5O2Purity:97.78% - 98.17%Color and Shape:SolidMolecular weight:411.54Balicatib
CAS:Balicatib is a small molecule that binds to the receptor on the surface of cancer cells and inhibits the activity of cathepsin. It has been shown to have an inhibitory effect on tumor growth in preclinical models by inhibiting tumor angiogenesis, preventing tumor cells from migrating, and inducing cell death. Balicatib has also been shown to be effective in reducing pain caused by diabetic neuropathy and cancer-related bone pain. Furthermore, balicatib is not metabolized by the liver and does not affect platelet aggregation.Formula:C23H33N5O2Purity:Min. 95%Molecular weight:411.54 g/mol
